Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal conbercept to prevent postoperative complications after vitrectomy for diabetic retinopathy
ChiCTR2100047351Phase 4Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jun 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of conbercept in diabetic retinopathy (DR), Vitreous hemorrhage (VH), diabetic macular edema (DME) and 1 more (2 arms), sponsored by Peking University Third Hospital. Primary endpoints: Incidence of vitreous hemorrhage, Incidence of diabetic macular edema and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
conbercept
03
Conditions
diabetic retinopathy (DR)Vitreous hemorrhage (VH)diabetic macular edema (DME)neovascular glaucoma (NVG)
Beyond the preview
Go deeper on ChiCTR2100047351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047351.